Market Overview

UPDATE: Deutsche Bank Raises PT to $115 on Perrigo Post Rosemont Acquisition

Share:
Related PRGO
RBC: Perrigo's Near-Term Risk Lessens, But Long-Term Issues Persist
5 Biggest Price Target Changes For Friday
102 Dividend Growth Stocks Going Ex-Dividend Next Week (Seeking Alpha)

Deutsche Bank maintained Perrigo (NASDAQ: PRGO) with a Hold rating and raised the price target from $110.00 to $115.00.

Deutsche Bank noted, "Perrigo announced on Monday the acquisition of UK-based Rosemont Pharmaceuticals for £180M or USD $283M in cash. … Rosemont appears to be a well diversified business, with 2012 sales of £40M (approx $60M, growing mid to high single digit over a number of years) from over 90 products – none more than 8% of revenue. This acquisition on the surface, however, looks a little expensive on a revenue multiple basis – at approximately 4.5x sales vs typical generic acquisition multiples of approximately 2.8x sales in recent years. That said, niche acquisitions in the generic injectables segment have garnered an average revenue multiple of 4.5x."

Perrigo closed at $111.40 on Monday.

Latest Ratings for PRGO

DateFirmActionFromTo
Nov 2017Morgan StanleyMaintainsEqual-Weight
Nov 2017RBC CapitalUpgradesUnderperformMarket Perform
Oct 2017UBSMaintainsBuy

View More Analyst Ratings for PRGO
View the Latest Analyst Ratings

Posted-In: Deutsche BankAnalyst Color Price Target Analyst Ratings

 

Related Articles (PRGO)

View Comments and Join the Discussion!

Partner Center